1,174 results on '"Stilgenbauer, Stephan"'
Search Results
2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network
3. Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation
4. Impairment of α-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion
5. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
6. T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia
7. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial
8. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies
9. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
10. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
11. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
12. Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
13. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
14. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis
15. Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics
16. Profile of the multicenter cohort of the German Cancer Consortium’s Clinical Communication Platform
17. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
18. Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic
19. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome
20. Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL
21. Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
22. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
23. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
24. Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia
25. Molecular map of chronic lymphocytic leukemia and its impact on outcome
26. The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
27. Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
28. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial
29. The scaffold protein NEDD9 is necessary for leukemia-cell migration and disease progression in a mouse model of chronic lymphocytic leukemia
30. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
31. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients
32. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia
33. Viral transduction of primary human lymphoma B cells reveals mechanisms of NOTCH-mediated immune escape
34. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
35. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
36. KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials
37. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
38. Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
39. Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry.
40. EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
41. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
42. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
43. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial
44. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
45. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia
46. Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas
47. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL
48. U-RT1 – A new model for Richter transformation
49. Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
50. Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.